VIDEO: ‘New hope on the horizon’ in psychedelic medicine
Click Here to Manage Email Alerts
NEW YORK — In this Healio Video Perspective, Reid Robison, MD, MBA, senior principal investigator at Numinus, a company that conducts clinical trials in psychedelics, discusses promising new treatment options for psychiatric conditions.
“There are a number of compounds that have fast-track designation from the FDA,” Robison said at the American Psychiatric Association Annual Meeting.
These include psilocybin for major depressive disorder and MM-120 (lysergide D-tartrate, MindMed) for generalized anxiety disorder, Robison said. In addition, he noted that esketamine (Spravato, Janssen) and off-label ketamine are available in clinic.
“It’s an encouraging and exciting time to be in psychiatry because we now have tools available, even in clinic, that show a rapid and robust clinical response, and there are more to come,” Robison said.